Bank of New York Mellon Corp increased its stake in Athersys, Inc. (NASDAQ:ATHX) by 11.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 265,165 shares of the biopharmaceutical company’s stock after buying an additional 26,526 shares during the period. Bank of New York Mellon Corp owned 0.24% of Athersys worth $453,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares in the last quarter. Old Mutual Global Investors UK Ltd. acquired a new position in Athersys during the first quarter valued at about $530,000. Teachers Advisors LLC boosted its position in Athersys by 21.9% in the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 28,178 shares during the last quarter. State Street Corp boosted its position in Athersys by 1.9% in the fourth quarter. State Street Corp now owns 1,119,590 shares of the biopharmaceutical company’s stock valued at $1,714,000 after buying an additional 20,680 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Athersys during the fourth quarter valued at about $617,000. 18.12% of the stock is owned by hedge funds and other institutional investors.
Athersys, Inc. (NASDAQ ATHX) remained flat at $1.69 during trading on Wednesday. 567,845 shares of the stock traded hands. Athersys, Inc. has a 52-week low of $1.02 and a 52-week high of $2.30. The stock’s market cap is $192.51 million. The firm’s 50-day moving average price is $1.59 and its 200 day moving average price is $1.42.
Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.96 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Equities research analysts expect that Athersys, Inc. will post ($0.24) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/08/16/athersys-inc-nasdaqathx-stake-increased-by-bank-of-new-york-mellon-corp-updated.html.
ATHX has been the subject of a number of research analyst reports. Maxim Group restated a “buy” rating on shares of Athersys in a research report on Wednesday, May 10th. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Monday.
In other Athersys news, EVP John J. Harrington sold 36,000 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $1.45, for a total value of $52,200.00. Following the transaction, the executive vice president now owns 712,743 shares in the company, valued at $1,033,477.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.40% of the company’s stock.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
